✦ LIBER ✦
P021 SUBCUTANEOUS CERTOLIZUMAB PEGOL IS WELL TOLERATED BY PATIENTS WITH ACTIVE CROHN'S DISEASE: RESULTS FROM TWO PHASE III STUDIES (PRECISE 1 AND 2)
✍ Scribed by S. Schreiber; B.G. Feagan; S.B. Hanauer; P. Rutgeerts; W.J. Sandborn
- Book ID
- 119637008
- Publisher
- Oxford University Press
- Year
- 2007
- Weight
- 59 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1873-9954
No coin nor oath required. For personal study only.